Chicken IgM ELISA Kit

Name: Chicken IgM ELISA Kit
SKU: DEIA629
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

COA

SDS

Datasheet

Sample

Serum, plasma, or other biological fluids

Species Reactivity

Chicken

Detection Method

Sandwich-ELISA

Intended Use

This enzyme linked immunosorbent assay (ELISA) is for the detection of Chicken IgM in serum, plasma, or other biological fluids.

Contents of Kit

No.	Components	Size	Storage Conditions
1	Chicken IgM Pre-Coated 96-well Strip Plate	1 each	2-8°C
2	Chicken IgM Standard, 500 ng/vial	2 each	2-8°C
3	Chicken IgM Detection Antibody	12 ml	2-8°C
4	10× Dilution Buffer B	25 ml	2-8°C
5	HRP Solution A	12 ml	2-8°C
6	TMB Substrate	12 ml	2-8°C
7	Stop Solution	12 ml	2-8°C
8	20× Wash Buffer	50 ml	2-8°C
9	Sealing Tape	6 sheets

Storage

Stored at 2-8°C for 6 months from date of receipt.

General Description

Avian antibodies have been recognized for decades and offer many advantages to mammalian antibodies in research and diagnostics. The only avian species in which antibodies are highly defined and easily accessible are the chicken. In mammals, immunoglobulins are classified into five groups: IgA, IgD, IgE, IgG and IgM. Chickens possess three principle classes of immunoglobulins: IgA, IgY (IgG) and IgM (Lebacq-Verheyden, 1974). Moreover, the structures of the corresponding immunoglobulins are significantly different, namely in the number of constant domains within the heavy chains. While avian IgY (IgG) is comprised of four constant domains, mammalian IgG contains only three (Hodek, 2003). Chicken IgM is the first antibody observed after primary immunization and IgM is expressed on the surface of most chicken B cells. During the course of an immune response, IgM is produced during the first week post-infection (Rathnapraba, 2007). The average concentration of IgM in chicken serum is about 2.55 mg/ml. IgM is also known to be transferred with other proteins in the oviduct into the egg white but in very low amounts.

Standard Curve

This typical standard curve was generated using the Chicken IgM ELISA Kit Protocol. This standard curve is for demonstration only. A standard curve must be generated for each assay.

*Suggested standard curve points are 500 ng/ml, 167 ng/ml, 55.6 ng/ml, 18.5 ng/ml, 6.17 ng/ml, 2.06 ng/ml, 0.69 ng/ml, and 0 ng/ml. Assay Range: 0.69 – 500 ng/ml

Citations

Have you cited DEIA629 in a publication? Let us know and earn a reward for your research.

Product Name	Cat. No.	Applications	Host Species	Datasheet	Price	Add to Basket

Product Name	Cat. No.	Applications	Host Species	Datasheet	Price	Add to Basket

Datasheet

Certificate of Analysis

Safety Data Sheet

Immunoassays for Process-related Impurities

Customer Reviews

Write a review

Cloning and mapping of cat (Felis catus) immunoglobulin and T-cell receptor genes

IMMUNOGENETICS

Authors: Cho, KW; Youn, HY; Okuda, M; Satoh, H; Cevario, S; O'Brien, SJ; Watari, T; Tsujimoto, H; Hasegawa, A

Abstract

Molecular cloning and chromosomal mapping of the cat immunoglobulin (Ig) and T-cell receptor (TcR) genes were carried out to provide basic information for genetic analysis of immunologic diseases including leukemias and lymphomas in cats. We cloned two ii: constant genes, IGHM and IGHG and three Ten constant genes, TRAC, TRGC, and TRDC, by polymerase chain reaction (FCR) amplification of cDNA from cat peripheral blood mononuclear cells. For chromosomal mapping of the ip and TcR loci including the IGK, TC;I, and TRB on the cat genome, we performed PCR screening of DNAs li-om 37 cat x rodent somatic cell hybrids by using specific primers for the given genes. Consequently, three loci for IGH, TRA, and TRD, and two loci for TRB and TRG were found to be syntenic and assigned to cat chromosomes (FCA) B3 and A2, respectively. Further, IGK and IGL loci were mapped on FCA A3 and D3, respectively. These findings support the notion that the genetic linkages between the Ig and TcR genes are extensively conserved between humans and cats.

Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma

SCIENCE TRANSLATIONAL MEDICINE

Authors: Jain, Neeraj; Hartert, Keenan; Tadros, Saber; Fiskus, Warren; Havranek, Ondrej; Ma, Man Chun John; Bouska, Alyssa; Heavican, Tayla; Kumar, Dhiraj; Deng, Qing; Moore, Dalia; Pak, Christine; Liu, Chih Long; Gentles, Andrew J.; Hartmann, Elena; Kridel, Robert; Smedby, Karin Ekstrom; Juliusson, Gunnar; Rosenquist, Richard; Gascoyne, Randy D.; Rosenwald, Andreas; Giancotti, Filippo; Neelapu, Sattva S.; Westin, Jason; Vose, Julie M.; Lunning, Matthew A.; Greiner, Timothy; Rodig, Scott; Iqbal, Javeed; Alizadeh, Ash A.; Davis, R. Eric; Bhalla, Kapil; Green, Michael R.

Abstract

The activated B cell (ABC-like) subtype of diffuse large B cell lymphoma (DLBCL) is characterized by chronic activation of signaling initiated by immunoglobulin mu (IgM). By analyzing the DNA copy number profiles of 1000 DLBCL tumors, we identified gains of 18q21.2 as the most frequent genetic alteration in ABC-like DLBCL. Using integrative analysis of matched gene expression profiling data, we found that the TCF4 (E2-2) transcription factor gene was the target of these alterations. Overexpression of TCF4 in ABC-like DLBCL cell lines led to its occupancy on immunoglobulin (IGHM) and MYC gene enhancers and increased expression of these genes at the transcript and protein levels. Inhibition of TCF4 activity with dominant-negative constructs was synthetically lethal to ABC-like DLBCL cell lines harboring TCF4 DNA copy gains, highlighting these gains as an attractive potential therapeutic target. Furthermore, the TCF4 gene was one of the top BRD4-regulated genes in DLBCL cell lines. BET proteolysis-targeting chimera (PROTAC) ARV771 extinguished TCF4, MYC, and IgM expression and killed ABC-like DLBCL cells in vitro. In DLBCL xenograft models, ARV771 treatment reduced tumor growth and prolonged survival. This work highlights a genetic mechanism for promoting immunoglobulin signaling in ABC-like DLBCL and provides a functional rationale for the use of BET inhibitors in this disease.